Fortitude Biomedicines launched with $13 million in seed funding to develop GLUE‑DACs—antibody‑drug conjugates that use targeted protein degraders (molecular glues) as payloads. The company argues that catalytic degraders can overcome established resistance mechanisms to conventional cytotoxic ADC payloads and expand ADC utility into immune and autoimmune indications. Fortitude’s launch reflects a broader industry pivot to combine established targeting platforms (antibodies) with next‑generation chemical modalities (PROTACs, molecular glues) to create new therapeutic classes. Investors and partners will watch preclinical tolerability and the ability to achieve targeted degradation in tumor cells without off‑target toxicity.